On January 24, it was reported that Chengda Biotech (688739) announced that the application for marketing approval of the quadrivalent influenza virus split vaccine developed by its wholly - owned subsidiary, Chengda Biotech (Benxi) Co., Ltd., for domestic drug production and registration had recently received the "Acceptance Notice" from the National Medical Products Administration. This vaccine is used to prevent influenza caused by influenza viruses of vaccine - related types. It has good safety and immunogenicity and can stimulate the body to produce immunity against influenza viruses.

If the quadrivalent influenza vaccine is successfully approved for marketing, it will enrich the company's product pipeline, enhance the company's core competitiveness, and lay a foundation for the company's sustainable and stable development. At the same time, the announcement pointed out that the acceptance of this application will not have a significant impact on the company's recent performance. In addition, the review and approval progress and the time to obtain the drug production registration approval document are somewhat uncertain. Investors need to make decisions carefully and pay attention to investment risks.

In the first three quarters of 2024, Chengda Biotech achieved revenue of 1.303 billion yuan and a net profit attributable to the parent company of 330 million yuan.

Source: https://finance.eastmoney.com/a/202501243307447342.html